Developmental pesticide models of the Parkinson disease phenotype.
Parkinson disease (PD) is a chronic neurodegenerative condition afflicting nearly one million people in the United States alone (McDonald et al. 2003). First described almost 200 years ago (Parkinson 1817), it is characterized clinically by resting tremor, rigidity, akinesia, and bradykinesia with a subsequent loss of postural stability. The sporadic form of the disease typically begins after 60 years of age. The basis for this movement disorder is a progressive loss of dopaminergic (DA) cells in the substantia nigra pars compacta, the neurons of the nigrostriatal DA system. The consequence is a loss of DA in the nigrostriatal system and thereby its control over motor function. Symptoms become evident after the loss of approximately 80% of these DA neurons. Characteristic of the accompanying pathology is the presence of Lewy bodies, which are intracytoplasmic inclusions containing neurofilament proteins and others such as [alpha]-synuclein and parkin. PD brings with it an extensive emotional and financial toll not only on the individuals affected but also on their families and the community. The disease is primarily idiopathic or sporadic; Mendelian-based genetic mutations account for less than 5% of the total cases of PD.
The cause(s) of PD remains unknown, and over the years the mechanism of genetic inheritance versus environmental exposures has been debated. It has become increasingly clear over the past several years, however, that multiple risk factors, both genetic and environmental, can produce parkinsonism (Figure 1). No single genetic mutation can account for most PD, an assertion underscored by the findings of a study by (Tanner et al. 1999) that examined more than 19,000 pairs of white male twins from the World War I1 veterans registry. The results showed no difference in concordance rates for PD in monozygotic and dizygotic twins 60 or more years of age. Nevertheless, at the current time, at least nine different genetic loci have been associated with the familial form of the disease (Hardy et al. 2003). These include mutations in the genes for [alpha]-synuclein and parkin, two of the proteins found in Lewy bodies. In environmental exposures, both pesticides and metals have been implicated as risk factors for PD, based on results from some epidemiologic studies (both metals and pesticides) as well as from experimental models (pesticides). A series of meta-analyses of such studies, including 16 based on living in rural areas, 18 for well-water drinking, 11 for farming, and 14 for pesticide exposures (Priyadarshi et al. 2001), concluded that all these variables may be risk factors for the development of PD.
[FIGURE 1 OMITTED]
Consistent with the potential for environmental exposures to contribute to the etiology of PD is the fact that the disease shows geographic variation in its mortality statistics. Such variation has been reported in Japan (Imaizumi 1995), Canada (Imaizumi 1995; Svenson 1990; Svenson et al. 1993), and the United States (Kurtzke and Goldberg 1988; Lanska 1997; Lilienfeld et al. 1990; Lux and Kurtzke 1987). Three studies using U.S. data show a north-to-south gradient for age-adjusted PD mortality. Figure 2 depicts results based on 1988 U.S. National Center for Health Statistics data (Lanska 1997). The highest PD rates occurred in the Northeast, Mid-Atlantic States, the Midwest, and the Pacific Coast states, with intermediate levels in the mountain states and in the Southwest and very low rates in the South, particularly from Texas to Florida. This is in contrast to other neurologic diseases: stroke mortality rates are particularly high in the Southeastern United States (Pickel et al. 1997), and cancers of the nervous system are lowest in Pacific states including California, Oregon, and Washington (Men& et al. 1998).
[FIGURE 2 OMITTED]
Also cited as evidence in support of environmental contributions to this disease is that PD occurs in greater frequency in industrialized countries. The PD prevalence rate is reportedly much lower in China than in the United States Li et al. 1985; Tanner et al. 1987, 1989), and even in China, PD appears to be associated with industrial chemical exposures (Tanner et al. 1989). A recent study examining PD mortality and pesticide exposure in California from 1984 through 1994 reported that mortality was increased in counties using agricultural pesticides after controlling for age, gender, race, birthplace, year of death, and education (Ritz and Yu 2000). The fact that the prevalence of PD in immigrant populations is comparable to the prevalence rate in the country of destination is also indicative of an environmental exposure basis of PD. For example, the prevalence of PD in Nigeria is lower than that for U.S. African Americans (Schoenberg et al. 1988); those of African Americans and whites in the United States are reported to be similar (Schoenberg et al. 1985), even though the African populations in the United States and Nigeria are largely homogeneous genetically after controlling for age and other variables that likely differ between countries. Similarly, Americans of Japanese or Okinawan ancestry have been reported to exhibit a PD incidence similar to that of white Americans, which is higher than that in Asian countries (Morens et al. 1996).
This apparent multiplicity of risk factors supports a growing belief that PD may be multifactorial in nature rather than a disease that can be ascribed to a unitary etiology. PD may be the result of the net interactions of multiple risk factors encountered over the lifetime, that is, a lifelong bionetwork of interactions, which in addition to those promoting risk, would also include factors that have shown to be protective against PD, such as caffeine and cigarette smoking (Baron 1986; Gorell et al. 1999; Kessler and Diamond 1971; Ross and Petrovitch 2001). Such a multifactorial etiology also would be consistent with PD because the disease exhibits marked heterogeneity with respect to signs and symptoms that manifest, the age of onset, and the rate of progression. For such reasons, it may be more appropriate to think of PD not as a unitary disease entity but rather as a broader phenotype. Such a premise may also explain why early studies that examined the potential for one such pesticide, paraquat (PQ), to produce parkinsonism were not particularly compelling (Bagetta et al. 1992; Marker et al. 1986; Perry et al. 1986). Investigators became interested in PQ particularly as a pesticidal risk factor because it shares a marked structural similarity to MP[P.sup.+] (1-methyl-4-phenylpyridinium), the most widely used experimental model of PD.
However, PQ exposure does not occur in isolation but instead occurs in conjunction with many other risk factors, including other environmental chemicals. Indeed, one can consider a type of multiple-hit hypothesis for the impact of multiple risk factors targeting the brain. Specifically, the brain may readily be able to compensate for the effects of an individual chemical alone acting on a particular system of the brain. However, when multiple target or functional sites within that particular system are attacked by different mechanisms (i.e., multiple chemical exposures or chemical exposures combined with other risk Factors), the system may no longer be able to homeostatically reregulate itself, thereby leading to sustained or cumulative damage. Figure 3 provides a hypothetical example featuring a DA terminal. Four concurrent insults are portrayed. Although all four insults target the DA terminal, they do so by different mechanisms, that is, at different sites of the same system. Here, for example, insult A targets the vesicular monoamine transporter in which DA is stored; insult B attacks the enzyme converting tyrosine to DOPA (3,4-dihydroxyphenylalanine) and thus the DA metabolic pathway; insult C strikes the metabolism of DOPAC (3,4-dihydroxyphenylacetic acid) to HVA (bomovanillic acid); and insult D hits the DA transporter that takes DA back up from the synaptic cleft postrelease. Multiple insults occurring concurrently at multiple sites within the system may constrict the range and flexibility of compensatory mechanisms, thereby compromising the integrity and viability of the system. As a consequence, mixtures could have effects that are more robust and more rapid in onset and that differ in character from effects produced by single exposures.
[FIGURE 3 OMITTED]
On the basis of such considerations, we posited that concurrent exposures to multiple pesticides that target the nigrostriatal DA systems but that do so through different mechanisms might provide more significant neurotoxicity (Cory-Slechta, in press). Thus, an exposure model was developed in young adult mice based on combined exposure to the herbicide PQ and the fungicide maneb (MB), based on their DA effects (Bagetta et al. 1992; Calo et al. 1990; Liou et al. 1996; Markey et al. 1986; Miller et al. 1991; Morato et al. 1989; Perry et al. 1986; Takahashi et al. 1989; Waiters et al. 1999; Yoshimura et al. 1993). PQ shares a remarkable structural similarity to MP[P.sup.+], the most widely used experimental model of the PD phenotype. MB actually enhances the effects of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; parent compound of MP[P.sup.+]). This model in young adult C57B1/6 mice was produced by administration of doses of 10 mg/kg pQ, 30 mg/kg MB, or combined PQ + MB, intraperitoneally (ip) twice a week for 6 weeks, for a total of 12 doses, and was shown to result in a PD phenotype (Thiruchelvam et al. 2000a, 2000b). In this phenotype, effects of PQ + MB were found to be potentiated; that is, for some measures, effects of combined PQ + MB were found where neither pesticide administered alone had any impact. The observed effects were, moreover, highly selective for the nigrostriatal DA system and irreversible. Additionally, studies using the PQ + MB model have shown a greater vulnerability of males to the combined treatment, which is consistent with observations from epidemiologic studies of PD (Wooten et al. 2004). These studies suggest that the greater incidence of the disease reported in males in epidemiologic studies may not only be due to greater exposures to potential environmental risk factors such as pesticides but also may be related to gender-based physiologic differences. Our studies also now indicate that both aging (Thiruchelvam et al. 2003) and overexpression of mutant human [alpha]-synuclein (Thiruchelvam et al. 2004) can enhance the PD phenotype produced by PQ + MB.
Developmental Insults and Parkinson Disease
Although PD is a neurodegenerative condition with a late-life onset, the possibility that it could be related to insults that occur early in life has been raised. Indeed, the pattern of manifestation of signs and symptoms should not be presumed to coincide with the timing of etiologic factors. Figure 4 depicts hypothetical models in which events occurring early in life could contribute or lead to PD later in life. Normal age-related degeneration in the DA system has been repeatedly described, which includes the loss of DA cell bodies as well as alterations that compromise the function of residual DA neurons (Anglade et al. 1997; Cabello et al. 2002; Calne and Langston 1983; Roth and Joseph 1994). Insults during the adult stage of the life cycle superimposed on such normal aging could further decrease DA function and lead more rapidly to the symptomatic PD range (< 20%; shaded area of Figure 4). It could be posited that events occurring early in development have long-term, delayed consequences for DA systems that may become evident only as the DA system undergoes further adult-related cell loss. For example, a developmental insult alone could accelerate the loss of DA neurons across life (solid red line), such that the percentage of DA function reaches the symptomatic PD range more rapidly. Adult insults superimposed upon such an enhanced decline, moreover, could further accelerate such a process (dashed red line). Alternatively, or in addition to these events, developmental insults could result in an early loss of DA neurons such that the entire curve of degeneration is displaced downward (solid green line) and again the symptomatic range is reached earlier in life, again, with such a possibility further accelerated by adult insults (dashed green line).
[FIGURE 4 OMITTED]
The potential for adverse effects of pesticide exposures to infants and children is of significant concern (Kimmel and Makris 2001; Mendola et al. 2002; Tilson 1998). Many pesticides were specifically designed to affect the nervous system of pests, but the phylogenetic parsimony of nervous system structure and function across species leaves humans at risk as well. This must be coupled with the fact that numerous factors contribute to the particular vulnerability of the developing nervous system to environmental chemical exposures. One is the complex series of events associated with brain development, which starts during the embryonic period and actually extends through adolescence. During this time, progenitor cells in the brain must travel in a defined time frame to their appropriate location and establish functional connections that are the basis for signals that ultimately underlie complex human behavior. In humans this period is primarily during the prenatal period. An additional factor operative early in life that can contribute to enhanced vulnerability of the brain is the incomplete development of the blood-brain barrier, including possible enhanced permeability to toxicants, or other examples of altered toxicokinetics. Although the barriers to blood-brain and blood-cerebrospinal fluid interfaces (i.e., tight junctions) are present from early in development, permeability to small lipid-insoluble molecules is greater in developing brain, and mechanisms of ion and amino acid transfer develop only sequentially with brain growth (Saunders et al. 1999).
Such possibilities raise at least three questions: a) Can developmental environmental insults lead to progressive or permanent nigrostriatal DA neurotoxicity? b) Will this insult alter vulnerability to subsequent environmental insults? c) Can such environmental insults produce cumulative neurotoxicity? The answers to such questions were pursued using the combined PQ + MB model described previously.
Subsequent studies using PQ + MB were undertaken to address the questions posed above with respect to exposures during development. Findings from these efforts attest to the significance of early development as a period of vulnerability for insults that later lead to a PD phenotype, demonstrating positive answers to all three questions. Indeed, findings from these studies also raise new and important issues concerning the adequacy of current risk assessment strategies.
Developmental Environmental Insults: Dopamine Neurotoxicity and Altered Vulnerability
Can developmental environmental insults lead to progressive or permanent nigrostriatal DA neurotoxicity? Will this insult alter vulnerability to subsequent environmental insults? To address these questions related to the potential for developmental insults to lead to a PD phenotype, C57B1/6 mice were exposed as shown in Figure 5 to the pesticides PQ + MB alone or in combination during postnatal days 5-19 at doses that were 1/30th of those used in the young adult studies (Thiruchelvam et al. 2002). Locomotor activity was assessed at 6 weeks and again at 6 months of age. In our studies, this measure has proven to be predictive of underlying nigrostriatal DA neuron loss. At 6.5-7.5 months of age, a subset of these mice were rechallenged with the same (adult) dosing regimen of the pesticides. Some mice were exposed to the pesticides only as adults. Approximately 2 weeks after the end of the adult rechallenge, locomotor activity was again evaluated, and brains were harvested thereafter for determinations of levels of DA and metabolites and for assessment of numbers of DA neurons using unbiased stereologic determinations.
[FIGURE 5 OMITTED]
Figure 6 depicts total locomotor activity (total horizontal activity counts across the duration of the session) measured in 45-min sessions at 6 weeks of age and again at 6 months of age, the latter determination occurring more than 5 months after pesticide exposure. Locomotor activity reductions were seen only in the PQ + MB group and not in response to either PQ or MB alone; that is, effects were potentiated. Reductions of 23% were evident in the PQ + MB group at 6 weeks of age, and by 6 months of age levels were further reduced by 38% relative to that of controls. Thus, these effects were progressive and could also be presumed to be permanent.
[FIGURE 6 OMITTED]
Changes in levels of DA and its metabolites were determined in striatum at the termination of the experiment, when mice were approximately 8-9 months of age. DA and DOPAC (3,4-dihydroxyphenylalacetic acid) levels are depicted in Figure 7 for groups that were exposed only during development or only as adults and those exposed developmentally and rechallenged as adults (developmental + adult). Relative to controls, developmental exposure to PQ alone decreased levels of DA, but these reductions were notably enhanced by combined PQ + MB, whereas MB alone had no impact. Similar but far less pronounced effects were seen in mice treated only as adults, where only PQ + MB produced significant reductions. The most dramatic effects were observed in groups treated developmentally and then rechallenged as adults, where reductions occurred in response to both PQ alone and MB alone, with even more marked effects in the group receiving PQ + MB, where levels of DA were reduced by 62% relative to those of controls. Moreover, developmental exposure followed by adult rechallenge unmasked silent toxicity apparently produced by MB treatment during development: although no changes were seen in response to developmental-only MB exposure, reductions did occur when it was followed by adult rechallenge with HB. A highly similar pattern of treatment-related effects was seen for DOPAC.
[FIGURE 7 OMITTED]
A similar but more marked profile of effects was observed for changes in T[H.sup.+] neurons (Figure 8). In this case even developmental-only exposures to PQ alone and to MB alone produced modest but statistically significant decreases in numbers of DA neurons in the substantia nigra pars compacta, and even larger reductions were found for combined PQ + HB. In adult-only exposures, both PQ alone and PQ + MB produced small but significant reductions (10-15%) in numbers of T[H.sup.+] neurons. The most dramatic effects were again seen in groups treated developmentally and then rechallenged as adults. Here, the reductions produced by PQ alone and HB alone were significantly greater than those observed in response to developmental-only exposures. So, too, was the reduction in the PQ + MB group, where the T[H.sup.+] neuron count decreased approximately 67% relative to control. These effects were not mirrored by changes in numbers of T[H.sup.-] neurons in the nigra (not shown) or by reductions in T[H.sup.+] neurons in the ventral tegmental area (region of cell bodies for the mesolimbic DA system; not shown); that is, these reductions were highly selective for the nigrostriatal DA system.
[FIGURE 8 OMITTED]
The protection of females from the effects of PQ + MB was particularly striking. For example, Figure 9 displays the changes in striatal levels of DA presented for males in Figure 6 and corresponding data for females. The reductions in DA levels produced by virtually all treatments were either attenuated or absent in females, with the exception of the reduction in DA in response to developmental exposure to PQ alone. The most obvious protection can be seen in comparing males with females in the groups exposed developmentally and rechallenged as adults. In these groups, females did show some reductions in levels of DA relative to those of their control group, but the magnitude of the effect was markedly reduced relative to the corresponding reductions observed in males.
[FIGURE 9 OMITTED]
This protection in females likewise extended to the reduction in numbers of T[H.sup.+] neurons in the substantia nigra pars compacta produced by these pesticide exposures, as shown in Figure 10. Figure 10 shows that the reductions produced by adult exposures, and particularly by developmental exposures followed by adult rechallenge were significantly reduced in females compared with males. The reductions produced in response to developmental-only exposures were, however, of generally comparable magnitude in the two genders, suggesting a postpubertal change. Collectively, these findings showing that protection in females is conferred postpuberty suggests that events associated with maturation of reproductive systems may play a role in this response.
[FIGURE 10 OMITTED]
It is important to note that the effects described in response to these treatments were seen in the absence of any indications of systemic toxicity in treated mice, including the lack of any weight loss; indeed, mice gained weight across the experiment. Nor were any gross histopathologic changes found. Thus, the effects observed are not a reflection in any sense of a generalized toxicity.
Can Such Environmental Insults Produce Cumulative Neurotoxicity?
Human exposures occur to mixtures over the life span, with the specific components of that mixture no doubt changing across time. One question raised by such exposure scenarios is whether sequential exposures across the lifetime would result in cumulative neurotoxicity to the nigrostriatal DA system. This too can be posited in the context of the multiple-hit hypothesis described previously, in that sequential and permanent damage to different target sites within the system could also result in compromise of homeostatic regulatory capacities. This question was pursued using the experimental design depicted in Figure 11. In this study C57B1/6 mice were exposed during gestation to saline or to MB only via administration to the dam of a dose of 1 mg/kg (1/10th the dose used in young adult studies) subcutaneously (sc) during gestational days 10-17, a time frame chosen to correspond to the emergence of the nigrostriatal DA system. Pups were weaned at 25 days of age, and locomotor activity was evaluated at 6 weeks of age, again as a preliminary gauge of underlying changes in the DA system. At approximately 2 months of age, a subset of mice was challenged with saline, with 5 mg/kg PQ alone, or with 30 mg/kg MB alone, the doses used with young adult mice, and these doses were administered daily for 8 days. One week later, locomotor activity was redetermined, and brains were harvested for determinations of levels of catecholamines and stereologic assessment of numbers of DA neurons (Barlow et al. 2004).
[FIGURE 11 OMITTED]
Findings from this study were largely unexpected. Changes in locomotor activity measured 7 days after the adult rechallenge are shown in Figure 12 for both males and females treated developmentally with saline or MB and rechallenged as adults with saline, PQ alone, or MB alone. With this particular exposure regimen, prenatal exposure to MB alone followed by adult rechallenge with PQ alone produced dramatic reductions in locomotor activity at this time point, effects that were seen only in males. Correspondingly, the reductions in levels of DA and of its metabolite DOPAC that were observed occurred only in response to prenatal MB exposure followed by adult rechallenge with PQ alone (Figure 13) and, again, in males but not in females. In addition, this regimen, that is, prenatal MB followed by adult rechallenge with PQ, produced a loss of T[H.sup.+] neurons that occurred selectively in the substantia nigra pars compacta and not in the ventral tegmental area (compare Figure 13A, B). Also, there were no changes in numbers of T[H.sup.-] neurons. Furthermore, females were protected from this loss of T[H.sup.+] substantia nigra neurons (Figure 14) as they were from the other adverse effects of prenatal MB followed by adult PQ exposure. As in the previous study (Thiruchelvam et al. 2002), these effects were seen in the absence of any indication of systemic toxicity, body weight loss, or gross histopathology.
[FIGURES 12-14 OMITTED]
Conclusions and Research Needs
These studies demonstrate the first examples of models of the PD phenotype based on developmental pesticide exposure. Our findings confirm that a developmental insult can have effects that appear to be progressive and permanent and ultimately lead to damage to the nigrostriatal DA system, including loss of T[H.sup.+] neurons (Figures 10, 14), consistent with the hypothetical models posed in Figure 4. In addition, both the postnatal and gestational exposure experimental models examined here showed that pesticide exposures during development increased vulnerability to subsequent pesticide exposures occurring later in life. These findings indicate that vulnerability can accumulate across insults, such that the effects of successive insults may actually be enhanced. Indeed, repeated insults also revealed underlying silent toxicity, wherein effects of developmental exposures to pesticides alone manifested only after adult rechallenge with the same or even a different pesticide. These findings also underscore the need for inclusion of childhood pesticide exposures in epidemiologic studies and further evaluation in experimental models.
The basis for the protection observed in females in these studies, mainly conferred postpubertally, is not yet clear. In addition to gender-related differences in time to onset of, magnitude of effects of and, perhaps, incidence that are reported in diseases and dysfunctions in which DA systems play a key role (e.g., attention deficit hyperactivity disorder, schizophrenia, PD), experimental studies have repeatedly demonstrated protective effects of estrogen in various experimental models, including protection against the DA toxicity associated with the experimental compound MPTP as well as against methamphetamine-induced DA toxicity (Dluzen and McDermott 2002; Dluzen et al. 1996; Miller et al. 1998). The mechanism(s) of such effects remains unknown and may be diverse but could include effects on DA release, on the DA transporter, and/or on the activity of tyrosine hydroxylase (TH), the rate-limiting enzyme in the DA synthesis pathway (Dluzen and McDermott 2000; Kuppers et al. 2000). This is a finding clearly warranting further experimental attention given the potential for therapeutic considerations.
One unexpected finding from these studies was the dramatic enhancement of the nigrostriatal dopaminergic toxicity associated with PQ treatment when it was administered in adulthood after developmental exposure to MB. The mechanisms responsible for this enhancement of toxicity, particularly given the time lag between treatments (~ 10 weeks), is not yet known. In adults the effects of PQ are potentiated by MB at least partly through a toxicokinetic interaction in which the levels of PQ in brain are increased and the rate of elimination from brain is decreased by co-administration with MB, effects that may be related to an inhibition of efflux transport of PQ by MB (Barlow et al. 2003). Clearly, such a mechanism cannot be operative in the current experiment using gestational MB followed by adult PQ given the time lag between exposures. Little is known about the neurotoxicity of MB, particularly during development. Another explanation eliminated by stereologic assessments is that the number of T[H.sup.+] neurons is already reduced by gestational exposure to MB alone such that PQ acted to further decrease these numbers, because no decrease in T[H.sup.+] neurons was produced by gestational MB followed by adult saline exposure (Figure 14). One possibility, however, is that MB established a "mutant steady state" (Clarke et al. 2000) in which the homeostatic state of those cells is abnormal and confers an increased rate of cell death in response to a subsequent challenge, a variant of the multiple-hit model posed in support of these experiments.
Even in the absence at the present time of an understanding of the specific mechanisms by which such augmentation of adverse effects can occur across delays of exposure between treatments, such findings raise serious questions about the adequacy of current risk assessment paradigms to encompass the patterns of toxicities observed in these studies. For example, the enhancement of the dopaminergic toxicity of PQ in adults by previous gestational exposure to MB would not necessarily have been predicted in advance; no structural similarities exist between these compounds, and they do not appear to act by identical mechanisms. Moreover, issues of cumulative toxicity, repeated insults, and exposures to mixtures are not addressed explicitly in the derivation of risk. Certainly, the question must be raised of whether the simple addition of uncertainty factors to a no-observed-adverse-effect levels in the risk assessment context would suffice to cover the toxicity produced by these sequential treatments. In addition the possibility that pharmaceuticals, herbal supplements, or food additives might interact with pesticides via toxicokinetic mechanisms, a phenomenon seen with MB potentiation of PQ effects, has not yet received sufficient consideration.
The brain, of course, consists of a complex network of highly interactive systems. This interactive matrix may account for the enhanced vulnerability of the brain under some conditions of neurotoxic chemical exposure. The occurrence of adverse effects anywhere within such circuits may result in disturbances across such networks and in associated behavioral output. Thus, the brain provides a more extensive matrix for damage than is seen in many other organs. In addition, direct effects at one point in such interactive systems may be amplified and produce indirect damage at other points within the network. Because different brain systems use common neurotransmitters for excitatory and inhibitory function, insults targeting neurotransmitter function per se, for example, receptors, transporters, or neurotransmitters, can have broad ramifications across the brain and thereby influence a wider array of behavioral functions.
The multiple-hit hypothesis of neurotoxicity upon which these studies were based postulates that insults to different target sites within a specific brain system, here the nigrostriatal DA system, when occurring concurrently or cumulatively, will compromise homeostatic and repair capacities of the system and thereby increase its vulnerability. Findings consistent with our hypothesis, as observed in these studies, suggest such a biologic plausibility rationale as a new strategy for defining potentially significant neurotoxic mixtures in a risk context for future studies, specifically mixtures of neurotoxicants acting on the same system of the brain but via different mechanisms of action.
This article is part of the mini-monograph "Early Environmental Origins of Neurodegenerative Disease in Later Life: Research and Risk Assessment."
Special thanks to the technical assistance of B. Goodman, and to R. Baggs (University of Rochester Medical School) for histopathologic analyses.
This work was supported by grants ES P30ES01247 and ES10791 from the National Institute of Environmental Health Sciences to I).C-S. and DAMD17-98-1-8628 from the U.S. Army to E.K.R.
The authors declare they have no competing financial interests.
Received 1 September 2004; accepted 31 March 2005.
Anglade P, Vyas S, Hirsch EC, Agid Y. 1997. Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. Histol Histopathol 12(3):603-510.
Bagetta G, Corasaniti MT, Iannone M, Nistico G, Stephenson JD. 1992. Production of limbic motor seizures and brain damage by systemic and intracerebral injections of paraquat in rats. Pharmacol Toxicol 71(6):443-448.
Barlow BK, Richfield EK, Cory-Slechta DA, Thiruchelvam M. 2004. A fetal risk factor for Parkinson's disease. Dev Neurosci 26(1):11-23.
Barlow BK, Thiruchelvam MJ, Bennice L, Cory-Slechta DA, Ballatori N, Richfield EK. 2003. Increased synaptosomal dopamine content and brain concentration of paraquat produced by selective dithiocarbamates. J Neurochem 85(4): 1075-1086.
Baron JA. 1986. Cigarette smoking and Parkinson's disease. Neurology 36(11):1490-1496.
Cabello CR, Thune JJ, Pakkenberg H, Pakkenberg B. 2002. Ageing of substantia nigra in humans: cell loss may be compensated by hypertrophy. Neuropathol Appl Neurobiol 28(4):283-291.
Calne DB, Langston JW. 1983. Aetielogy of Parkinson's disease. Lancet 2:1467-1459.
Cain M, Iannone M, Passafaro M, Nistico G. 1990. Selective vulnerability of hippocampal CA3 neurones after microinfusion of paraquat into the rat substantia nigra or into the ventral tegmental area. J Comp Pathol 103:73-78.
Clarke G, Collins RA, Leavitt BR, Andrews DF, Hoyden MR, Lumsden C J, et al. 2000. A one-hit model of cell death in inherited neuronal degenerations. Nature 406(6792):195-199.
Cory-Slechta DA. In press. Studying toxicants as single chemicals: does this strategy adequately identify neurotoxic risk? Neurotoxicology.
Dluzen DE, McDermott JL. 2000. Gender differences in neurotoxicity of the nigrostriatal dopaminergic system: implications for Parkinson's disease. J Gend Specif Med 3:36-42.
Dluzen DE, McDermott JL 2002. Estrogen, anti-estrogen, and gender: differences in methamphetamine neurotoxicity. Ann NY Acad Sci 965:136-156.
Dluzen DE, McDermott JL, Liu 8. 1996. Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice. Neurotoxicol Teratol 18(5):603-606.
Gorell JM, Rybicki BA, Johnson CC, Peterson EL. 1999. Smoking and Parkinson's disease: a dose-response relationship. Neurology 52(1):115-119.
Hardy J, Cookson MR, Singleton A. 2003. Genes and parkinsonism. Lancet Neurol 2:221-228.
Imaizumi Y. 1995. Geographical variations in mortality from Parkinson's disease in Japan, 1977-1985. Acta Neurol Scand 91:311-316.
Kessler II, Diamond EL. 1971. Epidemiologic studies of Parkinson's disease. I: Smoking and Parkinson's disease: a survey and explanatory hypothesis. Am J Epidemiol 94(1): 16-25.
Kimmel CA, Makris SL. 2001. Recent developments in regulatory requirements for developmental toxicology. Toxicol Lett 120(1-3):73-82.
Kuppers E, Ivanova T, Karolczak M, Beyer C. 2000. Estrogen: a multifunctional messenger to nigrostriatal dopaminergic neurons. J Neurocytol 29(5-6):375-385.
Kurtzke JF, Goldberg ID. 1988. Parkinsonism death rates by race, sex, and geography. Neurology 38:1558-1561.
Lanska DJ. 1997. The geographic distribution of Parkinson's disease mortality in the United States. J Neurol Sci 150: 63-70.
Li SC, Schoenberg BS, Wang CC, Cheng XM, Rui DY, Bolls CL, et al. 1985. A prevalence survey of Parkinson's disease and other movement disorders in the People's Republic of China. Arch Neurol 42(7):65.5-657.
Lilienfeld DE, Sekkor D, Simpson S, Perf DP, Ehland J, Marsh 6, et al. 1990. Parkinsonism death rates by race, sex and geography: a 1980s update. Neuroepidemiology 9(5):243-247.
Liou H-H, Chen R-C, Tsai Y-F, Chen W-P, Chang Y-C, Teal M-C. 1996. Effects of paraquat on the substantia nigra of the Wistar rats: neurochemical, histological, and behavioral studies. Toxicol Appl Pharmacol 137:34-41.
Lux WE, Kurtzke JF. 1987. Is Parkinson's disease acquired? Evidence from a geographic comparison with multiple sclerosis. Neurology 37:467-471.
Markey SP, Weisz A, Bacon JP. 1986. Reduced paraquat does not exhibit MPTP-like neurotoxicity [Letter]. J Anal Toxicol 10:257.
McDonald WM, Richard IH, DeLong MR. 2003. Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry 54(3):363-375.
Menck HR, Bland KI, Scott-Conner CE, Eyre HJ, Murphy GP, Winchester DP. 1998. Regional diversity and breadth of the National Cancer Data Base. Cancer 83:2649-2658.
Mendola P, Selevan SG, Butter S, Rice D. 2002. Environmental factors associated with a spectrum of neurodevelopmental deficits. Ment Retard Dev Disabil Res Rev 8(3):188-197.
Miller DB, Ali SE, O'Callaghan JP, Laws SC. 1998. The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann NY Acad Sci 844:153-165.
Miller DB, Reinhard JF, Daniels A J, O'Callaghan JP. 1991. Diethyldithiocarbamate potentiates the neurotoxicity of in vivo 1-methyl-4 phenyl-1,2,3,6-tetrahydropyridine and of in vitro 1-methyl-4-phenylpyridinium. J Neurochem 57(2): 541-549.
Morato BS, Lemos T, Takahashi RN. 1989. Acute exposure to maneb alters some behavioral functions in the mouse. Neurotoxicol Teratol 11(5):421-425.
Morens DM, Davis JW, Grandinetti A, Ross GW, Poper JS, White LR. 1996. Epidemiologic observations on Parkinson's disease: incidence and mortallity in a prospective study of middle-aged men. Neurology 46:1044-1050.
Parkinson J. 1817. An Essay on the Shaking Palsy. London: Sherwood Neely & Jones.
Perry TL, Yong VW, Wall RA, Jones K. 1986. Paraquat and two endogenous analogues of the neurotoxic substance N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine do not damage dopaminergic nigrostriatal neurons in the mouse. Neurosci Left 69:285-289.
Pickel LW, Mungiole M, Gillum RF. 1997. Geographic variation in stroke mortality in blacks and whites in the United States. Stroke 28:1639-1647.
Priyadarshi A, Khuder SA, Schaub EA, Priyadarshi SS. 2001. Environmental risk factors and Parkinson's disease: a meta-analysis Environ Res 86(2):122-127.
Ritz B, Yu F. 2000. Parkinson's disease mortality and pesticide exposure in California 1984 1994. Int J Epidemiol 29(2): 323-329.
Ross GW, Petrovitch H. 2001. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease. Drugs Aging 18(11):797-806.
Roth 6S, Joseph JA. 1994. Cellular and molecular mechanisms of impaired dopaminergic function during aging. Ann NY Acad Sci 719:129-135.
Saunders NR, Habgood MD, Oziegielewska KM. 1999. Barrier mechanisms in the brain. I1: Immature brain. Clin Exp Pharmacol Physiol 26(2):85-91.
Schoenberg BS, Anderson DW, Haerer AE. 1985. Prevalence of Parkinson's disease in the biracial population of Copiah County, Mississippi. Neurology 35:841 845.
Schoenberg BS, Osuntokun B0, Adeuja AOG. 1988. Comparison of the prevalence of Parkinson's disease in black populations in the rural US and in rural Nigeria: door-to-door community studies, Neurology 38:645-646.
Svenson LW. 1990. Geographic distribution of deaths due to Parkinson's disease in Canada: 1979-1986. Mov Disord 5(4):322-324.
Svenson LW, Platt GH, Woodhead SE. 1993. Geographic variations in the prevalence rates of Parkinson's disease in Alberta. Can J Neurol Sci 20:301-311.
Takahashi RN, Rogerio R, Zanin M. 1989. Maneb enhances MPTP neurotoxicity in mice. Res Commun Chem Pathol Pharmacol 66(1):167-170.
Tanner CM, Chen B, Wang W, Peng M, Liu Z, Liang X, et al. 1989. Environmental factors and Parkinson's disease: a case-control study in China. Neurology 39(5):660-664.
Tanner CM, Chen B, Wang WZ, Peng ML, Liu ZL, Liang XL, et al. 1987. Environmental factors in the etiology of Parkinson's disease. Can J Neurol Sci 14(3):419-423.
Tanner CM, 0ttman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, et al. 1999. Parkinson disease in twins. JAMA 281(4):341-346.
Thiruchelvam M, Brockel B J, Richfield EK, Baggs RB, Cory-Slechta BA. 2000a. Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease? Brain Res 873(2):225-234.
Thiruchelvam M, McCormack A, Richfield EK, Baggs RB, Tank AW, Di Monte DA, et al. 2003. Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. Eur J Neurosci 18(3):589-600.
Thiruchelvam M, Richfield EK, Baggs RB, Tank AW, Cory-Slechta DA. 2000b. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J Neurosci 20(24):9207-9214.
Thiruchelvam M, Richfield EK, Goodman BM, Baggs RB, Dory-Slechta DA. 2002. Developmental exposure to the pesticides paraquat and maneb and the Parkinson's disease phenotype. Neurotoxicology 23(4-5):621-633.
Thiruchelvam MJ, Powers JM, Cory-Slechta DA, Richfield EK. 2004, Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice. Eur J Neurosci 19(4): 845-854.
Tilson HA. 1998. Developmental neurotoxicology of endocrine disruptors and pesticides: identification of information gaps and research needs. Environ Health Perspect 106(suppl 3): 807-811.
Walters TL, Irwin I, Delfani K, Langston JW, Janson AM. 1999. Diethyldithiocarbamate causes nigral cell loss and dopamine depletion with nontoxic doses of MPTP. Exp Neurol 156:62-70.
Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J. 2004. Are men at greater risk for Parkinson's disease than women? J Neurol Neurosurg Psychiatry 75(4):637-639.
Yoshimura Y, Watanabe Y, Shibuya T. 1993. Inhibitory effects of calcium channel antagonists on motor dysfunction induced byintracerebroventricular administration of paraquat. Pharmacol Toxicol 72:229-235.
Deborah A. Cory-Slechta, (1,2,3) Mona Thiruchelvam, (1,2) Brian K. Barlow, (2) and Eric K. Richfield (1,3)
(1) Environmental and Occupational Health Sciences Institute, University of Medicine and Dentistry of New Jersey and Rutgers University, Piscataway, New Jersey, USA; (2) Department of Environmental and Occupational Medicine, and (3) Department of Pathology and Laboratory Medicine, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey, USA
Address correspondence to D.A. Cory-Slechta, Environmental and Occupational Health Sciences Institute, 170 Frelinghuysen Rd., Piscataway, NJ 07920 USA. Telephone: (732) 445-0205. Fax: (732) 445-0131. E-mail: email@example.com
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Research / Mini-Monograph|
|Author:||Richfield, Eric K.|
|Publication:||Environmental Health Perspectives|
|Date:||Sep 1, 2005|
|Previous Article:||Aging and the environment: a research framework.|
|Next Article:||Science education: the future begins today!|